Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Edwards Lifesciences (EW) PT Raised to $153 at RBC Capital
October 24, 2018 6:59 AM EDTRBC Capital analyst Glenn Novarro raised the price target on Edwards Lifesciences (NYSE: EW) to $153.00 (from $145.00) while maintaining an Outperform rating.
Novarro notes management commentary on 3Q call moderates our 2019 THV growth outlook.
... MoreEdwards Lifesciences (EW) Tops Q3 EPS by 5c, Offers Q4 Guidance
October 23, 2018 4:20 PM EDTEdwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.07, $0.05 better than the analyst estimate of $1.02. Revenue for the quarter came in at $907 million versus the consensus estimate of $928.18 million.
GUIDANCE:
Edwards Lifesciences sees Q4 2018 EPS of $1.05-$1.20, versus the consensus of $1.21.... More
